Control group | TXA 250 mg | TXA 500 mg | p-value | |
---|---|---|---|---|
(nā=ā45) | (nā=ā45) | (nā=ā45) | ||
WOMAC scoreā | ||||
āāāāā 3 months | 36.7 (8.2)** | 35.8 (7.6)** | 35.5 (7.2)** | 0.42 |
āāāāā 6 months | 25.4 (6.0)** | 23.1 (6.5)** | 23.5 (6.6)** | |
āāāāā 1 year | 15.5 (6.6)** | 15.1 (6.2)** | 14.5 (7.1)** | |
āāāāā p-value within group | < 0.001** | < 0.001** | < 0.001** | |
Knee society knee scoreā | ||||
āāāāā 3 months | 121.7 (10.2)** | 121.1 (10.1)** | 123.3 (9.1)** | 0.91 |
āāāāā 6 months | 141.0 (11.5)** | 141.2 (9.4)** | 140.0 (8.9)** | |
āāāāā 1 year | 148.9 (10.1)** | 151.2 (9.1)** | 150.9 (9.3)** | |
āāāāā p-value within group | < 0.001** | < 0.001** | < 0.001** | |
Complicationsā | ||||
āāāāā Re-clamp | 6 (13%) | 1 (2%) | 0 (0%)*b | 0.01 |
āāāāā Re-dressing | 3 (7%) | 0 (0%)*a | 0 (0%)*b | 0.05 |
āāāāā VTE | 4 (9%) | 1 (2%) | 2 (4%) | 0.35 |
āāāāā Congestive heart failure | 0 (0%) | 1 (2%) | 0 (0%) | 1.00 |